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A B S T R A C T
Despite advances in drug therapy for the treatment of atrial fibrillation (AF), there 
continues to be a need for antiarrhythmic agents that have improved safety and effica-
cy profile. Unfortunately, drugs that block the potassium channels or are multichannel 
blockers, although they may be effective antiarrhythmics, they delay repolarization 
and thus they confer a proarrhythmic effect by inducing torsade de pointes, a po-
tentially lethal ventricular arrhythmia. Most newer antiarrhythmic drugs are potas-
sium channel blockers and this limits their usefulness. A less toxic agent compared 
to amiodarone, the noniodinated analogue of amiodarone (dronedarone) is being 
investigated; however, it appears already unsafe in patients with heart failure. Future 
antiarrhythmic agents will probably be atrial-selective blocking agents without affect-
ing repolarization in the ventricular myocardium and thus avoid ventricular proar-
rhythmia with its attendant life-threatening consequences.
I N T R O D U C T I O N
Despite advances in drug therapy for the treatment of atrial fibrillation (AF), 
there continues to be a need for antiarrhythmic agents that have improved safety and 
efficacy profile.1-7 The wavelength in the atrium plays a critical role in AF. The two 
fundamental mechanisms of antiarrhythmic drugs in terminating AF include slowing 
of conduction and lengthening of repolarization and refractoriness. In the wake of 
the CAST trial demonstrating the proarrhythmic properties of agents with selectivity 
for sodium channels, when used as antiarrhythmic drugs in patients with significant 
underlying structural heart disease, attention switched to drugs inhibiting potassium 
channels. They terminate and/or prevent AF by lengthening action potential duration 
and the effective refractory period. Unfortunately, drugs that delay repolarization 
can induce polymorphic ventricular tachycardia in the form of torsade de pointes, a 
potentially lethal proarrhythmic effect.
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C l A S S  I I I  A N T I A R R h y T h m I C  D R U g S
D O f e T I l I D e
The antiarrhytmic effects of dofetilide8,9 are due to its abil-
ity to block the fast component of the repolarizing potassium 
current IKr, resulting in an increase of the action potential 
duration and prolonged effective refractory period without 
altering conduction velocity. The drug half-life is 8 to 10 
hours, and steady-state plasma concentrations are achieved 
within two to three days. Approximately 80% of dofetilide 
is renally eliminated. Dofetilide has been shown to be effec-
tive for the treatment of AF or atrial flutter in patients with 
structural heart disease, with neutral effects on mortality. 
Although free of noncardiac adverse effects, dofetilide is 
associated with proarrhythmic effects, primarily torsade de 
pointes (TdP) which has been reported to range in frequency 
from 0.6 to 2.9%. The risk of TdP increases when dofetilide 
is administered to patients with a prolonged baseline QT in-
terval, electrolyte abnormalities, or renal impairment without 
dosage adjustment. Most cases of Tdp occur during the first 3 
days of treatment. Therefore, FDA has mandated that patients 
started or restarted on dofetilide therapy should be placed, for 
a minimum of three days, in a facility that can provide creati-
nine clearance calculations, continuous electrocardiographic 
(ECG) monitoring, and cardiac resuscitation. Data from clini-
cal studies, which enrolled about 1000 patients, demonstrated 
that conversion to sinus rhythm occurs in 30% of patients, but 
these data are mainly related to long-lasting AF episodes. In 
addition to being an effective agent for medical conversion 
of AF to sinus rhythm, dofetilide had a 58% efficacy rate in 
maintaining sinus rhythm at 1-year postcardioversion com-
pared with only 25% in the placebo group in the SAFIRE-D 
trial.9 Results for maintaining sinus rhythm in the EMERALD 
trial were similar.9 In both trials, efficacy was dose related. 
According to the recent ACC/AHA/ESC treatment guidelines 
for AF,10 dofetilide and amiodarone are the two drugs sug-
gested for use in patients with heart failure.
I B U T I l I D e
Ibutilide11,12 is a novel antiarrhythmic agent that prolongs 
action potential duration by enhancing sodium exchange 
during phase 2 of the action potential with a lesser effect in 
blocking the outward potassium current (Kr). It is available 
only as an intravenous agent. Ibutilide is metabolized exten-
sively in the liver. The half-life of ibutilide and its metabolite 
is 4 to 8 hours. It appears to work better in patients with AF 
of relatively recent onset and has greater efficacy in atrial 
flutter. In a prospective comparative trial, ibutilide was more 
effective than procainamide and reverted 35 to 40% of patients 
to sinus rhythm within 1 hour of administration, compared 
with only 20% of the procainamide group. In another study, 
ibutilide was more effective than sotalol in terminating AF. 
Its use must be strictly monitored with ECG because of the 
risk of torsade de pointes (1-5% of cases), which occurs more 
often in female patients, and in the presence of heart failure, 
hypokalemia, long QT at baseline ECG and organic heart dis-
ease. Although ibutilide is hemodynamically well tolerated in 
patients with ventricular dysfunction, the incidence of torsade 
de pointes is increased in patients with an ejection fraction of 
<35% and therefore must be used with caution in this setting. 
Ibutilide can also be used to lower the cardioversion energy 
requirement in patients refractory to cardioversion. The drug 
has been shown to have an enhanced efficacy in AF or atrial 
flutter conversion when added to propafenone.
A z I m I l I D e
Azimilide,13-15 an antiarrhythmic agent with Vaughan-
Wiliams class III activity, blocks fast and slow components of 
the cardiac delayed rectifier potassium channels. The proper-
ties of azimilide differ somewhat when compared with other 
pure Class III agents in terms of the drug’s effect relative to 
changes in heart rate (use dependence). Azimilide has a long 
elimination half-life of 114 hours, and is hepatically cleared. 
Recent data from the ALIVE trial has shown that azimilide 
has neutral effect on survival in a high-risk post-myocardial 
infarction population. Randomized, placebo-controlled 
clinical trials have shown that it was effective in patients with 
AF in prolonging the time to symptomatic arrhythmia recur-
rence. Azimilide was given to patients with a broad range of 
associated heart diseases including congestive heart failure 
and ischemic heart disease. The most effective dose appears 
to be 125 mg/day, with efficacy rates of about 50%. Azimilide 
prolongs the QTc on the ECG and is associated with infrequent 
cases of torsade de pointes (0.9%). A low incidence of drug-
induced neutropenia has been reported.
D R O N e D A R O N e
Dronedarone16-18 is a benzofuran derivative, structurally 
related to amiodarone, i.e. the noniodinated analogue of 
amiodarone. It has an electrophysiologic profile similar to 
that of amiodarone, but its lack of iodine makes it a promising 
alternative to amiodarone. To date, end organ toxicity has not 
been reported. Dronedarone has an elimination half-life of 24 
hours, with steady-state levels being achieved in 5 to 7 days. 
It is an Kr, Ks, to, fast sodium and calcium antagonist. Dron-
edarone is a potent inhibitor of the acetylcholine-activated 
K+ current and like amiodarone shows an antiadrenergic 
action. It prolongs action potential duration in the atria and 
ventricles, slows sinus rate and prolongs AV nodal refractory 
period. In the Dronedarone Atrial Fibrillation Study After 
Electrical Cardioversion (DAFNE) trial, dronedaronre 800 
mg/day appeared to be effective and safe for the prevention 
of AF relapses after cardioversion. The Antiarrhythmic Trial 
in Moderate-to-Severe Congestive Heart Failure Evaluating 
Morbidity Decrease (ANDROMEDA) trial was stopped due 
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to potential increased risk of death in the dronedarone group. 
Trials of dronedarone in the maintenance of sinus rhythm 
in patients with AF or flutter (EURIDIS, ADONIS)18 have 
shown that dronedarone was more effective than placebo in 
maintaining sinus rhythm and in reducing the ventricular rate 
during recurrence of AF.
T e D I S A m I l
Tedisamil,19 is different from other pure Class III an-
tiarrhythmic agents, because it blocks a complex aggregate of 
repolarizing ionic currents, has anti-ischemic properties, and 
slows the heart rate. Intravenous tedisamil rapidly converts 
recent onset AF. However, the program for tedisamil was 
temporarily interrupted because of concerns over the drug’s 
possible proarrhythmic effects.
f U T U R e  A N T I A R R h y T h m I C  D R U g S
5-HT4 receptors are present in human atrial cells and 
when stimulated may cause atrial arrhythmias. Antagonists to 
5-HT4 receptors have been developed (piboserod, SB203186) 
and currently are being used in clinical trials. It is unknown at 
this time, whether this drug class will have a clinical role.
Certain potassium channels such as ultrarapid delayed 
rectifier (Kur) and acetylcholine-sensitive potassium channel 
(KACh) are predominantly present in the atria and marginally 
present or absent in the human ventricle and play an important 
role in the atrial resting potential. Therefore, antiarrhythmic 
drugs, atrial-selective agents that modify the function of these 
channels could be important for the treatment of supraven-
tricular arrhythmias, without the potential risk of inducing 
ventricular arrhythmias. The selective IKur blockers S1185, 
S9947, S20951, and RSD1235 (vernakalant)20,21 effectively 
decreased atrial vulnerability in animals by preferentially 
increasing left atrial refractory period. In contrast to dofeti-
lide, azimilide, and sotalol, they did not prolong ventricular 
refractoriness. Another promising antiarrhythmic drug under 
development is AVE0118. This IKur and Ito blocker preferen-
tially increased atrial refractoriness in electrically remodeled 
atria and was able to convert persistent AF without lengthen-
ing the QT interval.
Another target that may be useful for future antiarrhyth-
mic drug action is the stretch activated-channels caused by 
hemodynamic changes, which are believed to be involved in 
the genesis of some arrhythmias. It has been recently shown 
that the peptide GsMtx-4, found in the venom of the taran-
tula Grammostola spatulata, could selectively block cationic 
stretch-activated channels in cardiac myocytes and reduce the 
incidence and the duration of AF episodes that are induced 
by bursts of rapid atrial stimulation. Data from animal studies 
showed that gadolinium chloride suppressed stretch-activated 
arrhythmias. Unfortunately, gadolinium chloride is toxic to 
the heart because of its nonselective displacement of calcium 
and other ions from membrane sites, and thus cannot be used 
as an antiarrhythmic agent. ZP123 which facilitates conduc-
tion in the gap junction and drugs that are long-lasting A-1 
adenosine antagonists are under development.
Finally, based on the molecular and cellular investigations 
of the mechanisms involved in the initiation and maintenance 
of AF, novel approaches, mainly targeting the intracellular 
calcium overload, are currently being investigated.
It is clear that we need better antiarrhythmic drugs with 
less attendant cardiac and organ toxicity. Several new agents 
are under investigation and the impact they will have on AF 
management remains to be seen.
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